All In MedTech

FDA Clearance Tracker · P190008

IN.PACT AV Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Nov 21, 2019 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Nov 21, 2019

Approved

Time to decision

232 days

Received Apr 3, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P190008
Device name
IN.PACT AV Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter
Applicant location
Santa Rosa, CA
Received
Apr 3, 2019
Decided
Nov 21, 2019
Decision
Approved
Supplements
46 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code PRC

FDA's approval statement

As written in FDA's record.

Approval for the IN.PACT AV Paclitaxel-coated PTA Balloon Catheter. The device is indicated for percutaneous transluminal angioplasty, after appropriate vessel preparation, for the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PRC. The earliest in FDA's data is P170003, decided Aug 25, 2017.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic Vascular, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.